Broadstreet is very pleased to be welcoming an old friend and new vice president to the team, Suzanne McMullen. She has known Shelagh and Karissa since the early days of her career in HEOR, when they all worked at Oxford Outcomes. She describes their mentorship back then as a significant factor in her career trajectory. Her time at Oxford Outcomes gave her the opportunity to gain experience in various aspects of the health economics and outcomes research sector, as well as epidemiology, which became her specialty.
After Oxford Outcomes was acquired by ICON Plc. she honed her expertise in real world evidence (RWE), spending a lot of her time on multi-national projects including prospective studies, retrospective database and chart reviews, and eliciting patient, caregiver and provider perspectives. At ICON, Suzanne eventually rose to the position of Principal of Epidemiology. She joined Medlior Health Outcomes Research in 2020 leading the RWE and analytics work, eventually becoming Vice President of Research and Innovation. With over 15 years of HEOR consulting experience, she has worked in numerous therapeutic spaces including but not limited to oncology, cardiology, endocrinology, rare diseases, neurology and infectious diseases.
While she finds many aspects of HEOR fascinating, she has a particular interest in RWE which has grown over the course of her career in HEOR consulting. Over that time, she has had the opportunity see and understand the impact RWE can provide in areas as diverse as addressing points of uncertainty in clinical trials, capturing the patient and caregiver voice and promoting health equity. She has considerable experience with high level strategic consulting to ensure companies are developing RWE that supports gaps in their clinical programs. For her, the value of RWE is the potential to provide better data for decision making and therefore better outcomes for patients. The heterogenous populations in database studies or chart reviews are more reflective of the real world and thus provide the potential to capture insights in may not be possible to ascertain in the trial setting. In addition to her work in RWE, she has extensive experience with facilitating advisory boards (e.g., consensus building, development of diagnostic or education tools or to inform strategic planning) and evidence strategizing. Suzanne has already hit the ground running at Broadstreet and it’s clear she is going to be a considerable asset to the team.
